Psychemedics Corp.

As of March 29, 2022, Psychemedics Corp. is considered overvalued and risky due to poor financial metrics, a Price to Book Value of 2.93, an EV to EBITDA ratio of 14.29, and a one-year stock return of -8.88%, significantly underperforming compared to the S&P 500's 17.14% return.

As of June 11, 2025, Psychemedics Corp. exhibits a neutral technical stance with mixed indicators, showing a shift from mildly bullish to sideways, as the weekly MACD is bearish while the monthly MACD is mildly bullish, and Bollinger Bands indicate downward pressure.

As of March 29, 2022, Psychemedics Corp. is considered overvalued and risky due to its negative P/E ratio, poor returns on capital, and a significantly higher EV to EBITDA ratio compared to peers, alongside a disappointing long-term stock performance.

As of March 2022, the management team of Psychemedics Corp. includes Mr. Raymond Kubacki as Chairman, President, and CEO, along with independent directors Mr. A. Clinton Allen, Mr. Harry Connick, Mr. Walter Tomenson, and Mr. Fred Weinert.

Psychemedics Corp. specializes in hair testing for drug abuse and operates in the micro-cap market, with a market cap of $15.25 million and quarterly net sales of $4 million as of December 2024. The company currently reports no net profit and has a negative return on equity of -36.24%.

As of Jun 18, Psychemedics Corp. has a market capitalization of 15.25 million and reported net sales of 19.68 million with a net profit of -1.87 million over the latest four quarters.